视频

Identification of Mycobacterium tuberculosis  BioA inhibitors by using structure-based virtual screening

 

Authors Singh S, Khare G, Bahal RK, Ghosh PC, Tyagi AK

Received 17 June 2017

Accepted for publication 28 September 2017

Published 1 May 2018 Volume 2018:12 Pages 1065—1079

DOI https://doi.org/10.2147/DDDT.S144240

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 4

Editor who approved publication: Dr Sukesh Voruganti

Background: 7,8-Diaminopelargonic acid synthase (BioA), an enzyme of biotin biosynthesis pathway, is a well-known promising target for anti-tubercular drug development. 
Methods: In this study, structure-based virtual screening was employed against the active site of BioA to identify new chemical entities for BioA inhibition and top ranking compounds were evaluated for their ability to inhibit BioA enzymatic activity. 
Results: Seven compounds inhibited BioA enzymatic activity by greater than 60% at 100 µg/mL with most potent compounds being A36, A35 and A65, displaying IC
50 values of 10.48 µg/mL (28.94 µM), 33.36 µg/mL (88.16 µM) and 39.17 µg/mL (114.42 µM), respectively. Compounds A65 and A35 inhibited Mycobacterium tuberculosis  (M. tuberculosis ) growth with MIC90 of 20 µg/mL and 80 µg/mL, respectively, whereas compound A36 exhibited relatively weak inhibition of M. tuberculosis  growth (83% inhibition at 200 µg/mL). Compound A65 emerged as the most potent compound identified in our study that inhibited BioA enzymatic activity and growth of the pathogen and possessed drug-like properties.
Conclusion: Our study has identified a few hit molecules against M. tuberculosis  BioA that can act as potential candidates for further development of potent anti-tubercular therapeutic agents.
Keywords: Mycobacterium tuberculosis , BioA, virtual screening, drug discovery


 

摘要视频链接Identification of Mycobacterium tuberculosis  BioA inhibitors